Share this article
Share this article
OSLO, Norway, March 1, 2021 /PRNewswire/ The board of directors of Targovax ASA (OSE:TRVX) ( Targovax or the Company ) has resolved to increase the share capital of the Company following the completion of an exercise period for vested share options under the Company s long-term incentive program for employees. The exercise period for the LTI program commenced on 19 February 2021 at 10:00 hours (CET) and ended on 1 March 2021 at 10:00 hours (CET).
1. Exercise of options
In total, 29,788 options were exercised, giving the option holders the right to subscribe for 29,788 shares, each with a par value of NOK 0.10, of which:
Continued survival benefit in Targovax s ONCOS-102 trial in mesothelioma at the 21-month follow-up
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Continued survival benefit in Targovax s ONCOS-102 trial in mesothelioma at the 21-month follow-up
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Share this article
OSLO, Feb. 18, 2021 /PRNewswire/
Targovax ASA, a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, will host a virtual Capital Markets Day for investors, analysts and journalists today at 2:30 PM CET. The Capital Markets Day will feature presentations from executive management and Alexander Shousthari, Clinical Director Melanoma Services at Memorial Sloan Kettering Cancer Center, and will be webcast live and accessible at https://www.targovax.com/en/capital-markets-day-2021/
Based on the strong clinical data that are now generated on ONCOS-102, Targovax has a solid fundament to move into late stage clinical development. We also have a broader pipeline of preclinical assets that could create a broader horizon of opportunities in the future. The Capital Markets day will feature presentations updating the market on these aspects.
Share this article
OSLO, Norway, Feb. 15, 2021 /PRNewswire/
Targovax ASA (OSE: TRVX), a clinical stage immune-oncology company developing immune activators to target hard-to-treat solid tumors, today announces that its lead clinical candidate ONCOS-102 has received Fast-Track designation in malignant pleural mesothelioma from the US FDA.
The US FDA granted Fast-Track designation to ONCOS-102 based on encouraging pre-clinical and clinical efficacy associated with broad immune activation observed to date. Receiving this designation is an endorsement by the US FDA of the strength of the ONCOS-102 data package.
The FDA Fast Track-designation is awarded to therapies with potential to address unmet medical needs in serious medical conditions and allows for more frequent interactions with the FDA to expedite clinical development, as well as the regulatory review processes. Fast-Track products have improved likelihood of receiving Priority Review for a future Biologics License Appl